There are more than 20,000 drugs approved for sale in the United States, and over the course of time, the sales of these drugs ebb and flow based on many factors. But some stay the course of time and reveal new indications or uses based on renewed clinical research. Here are five “old” drugs that are enjoying a renaissance right now, including thalidomide and its long, dark history.

Doctors, along with the rest of the nation, are drinking more during the pandemic. Five or more drinks a week is now standard fare for about 30% of Baby Boomer physicians, 26% of Generation X physicians, and 22% of Millennial doctors, up from the previous year by about 7%. But which specialties are drinking the most? Find out in this revealing report.

Just like how a great player will not necessarily make a great coach, not all physicians or healthcare providers are cut out to be health leaders. The smallest details are important, and the absolute best medical leaders can improve patient outcomes and staff morale while influencing positive change and inspiring others. Learn if you’ve got the chops for leadership by viewing these eight qualities of effectiveness.

In this Original Investigation from JAMA, the authors discuss the results of a randomized clinical trial that included 208 patients with high- and intermediate-risk first relapse of B-cell acute lymphoblastic leukemia (ALL). Did postreinduction treatment with blinatumomab compared with chemotherapy, followed by hematopoietic stem cell transplant, result in a statistically significant difference in disease-free survival?

As of February 8, 2021, more than 31 million people in the U.S. had received at least one dose of the coronavirus vaccine, with 36 cases of immune thrombocytopenia (ITP) reported to the Vaccine Adverse Event Reporting System by the end of January. Is the onset of the condition related to the vaccines? The vaccines are considered safe overall, but what did the CDC and FDA have to say about it?

For the estimated 21,000 patients who will receive a diagnosis of chronic lymphocytic leukemia (CLL), 20% of them will have early-stage disease. Unfortunately, that 20% will not be offered treatment, as the current management of these patients follows a “watch-and-wait” paradigm. However, with the advent of better prognostic tools to identify patients at high risk, in addition to the recent approval of several novel oral agents with impressive efficacy, re-examining this approach now seems prudent.